| lerociclib (G1T38) / Walvax, Pepper Bio |
| Completed | 3 | 275 | RoW | GB491+ Fulvestrant, test drug + Fulvestrant, Placebo+Fulvestrant, placebo control + Fulvestrant | Genor Biopharma Co., Ltd. | Locally Advanced or Metastatic Breast Cancer | 12/22 | 03/24 | | |
ENGOT-EN17, NCT05712941: Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients With Advanced/Metastatic or Recurrent, Grade 1 or Grade 2 Endometrial Cancer |
|
|
| Withdrawn | 3 | 320 | NA | Lerociclib, Letrozole 2.5mg, Placebo | EQRx International, Inc., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT) | Endometrial Carcinoma | 03/24 | 03/25 | | |
LEONARDA-2, NCT05851014: A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer |
|
|
| Recruiting | 3 | 350 | RoW | GB491 combined with Letrozole, Placebo combined with Letrozole | Genor Biopharma Co., Ltd. | Breast Cancer | 01/26 | 01/27 | | |
| Terminated | 2 | 100 | Europe, US, RoW | Lerociclib + Letrozole or Fulvestrant | EQRx, Inc. | Advanced Breast Cancer | 11/23 | 11/23 | | |
NCT02983071 / 2016-001485-29: G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer |
|
|
| Active, not recruiting | 1/2 | 102 | Europe, RoW | G1T38, lerociclib, Fulvestrant, Faslodex | G1 Therapeutics, Inc. | Carcinoma, Ductal, Breast, Breast Cancer, Breast Neoplasm | 06/23 | 10/23 | | |
| Completed | 1 | 6 | RoW | [14C]GB491 | Genor Biopharma Co., Ltd. | Breast Cancer, Nonsmall Cell Lung Cancer | 11/22 | 11/22 | | |
NCT05337657: A Phase Ib Study of GB491 Plus Letrozole in Patients With Advanced Breast Cancer |
|
|
| Recruiting | 1 | 10 | RoW | GB491+Letrozole | Genor Biopharma Co., Ltd. | Advanced Breast Cancer | 12/23 | 02/24 | | |
